Anthropic and medical knowledge platform OpenEvidence are partnering to make AI-based clinical decision support available to doctors in around 100 countries. The initiative focuses on low- and middle-income countries, where doctors may have limited access to medical research, treatment guidelines and specialist expertise.
The companies announced the partnership on September 22, 2026. As part of the initiative, healthcare professionals in dozens of low- and middle-income countries will receive free access to a specialized version of OpenEvidence.
OpenEvidence uses medical research, clinical guidelines and other trusted sources to help doctors answer clinical questions and make informed decisions about patient care. The platform is already available at no cost to clinicians in the United States and Europe.
The global rollout will include countries such as Uganda, Angola, Sudan, Haiti and Mongolia, according to a list released by OpenEvidence. Anthropic and OpenEvidence said the platform will be adapted to the healthcare needs and conditions of different countries rather than using the same approach everywhere.
Anthropic Will Provide the AI Technology
Under the partnership, Anthropic will provide the underlying AI technology, while OpenEvidence will adapt its platform for use in different countries and healthcare systems.
The companies say medical AI cannot be deployed in the same way everywhere. Differences in local disease patterns, healthcare infrastructure, diagnostic tools and available treatments need to be considered when bringing the technology to countries with fewer healthcare resources.
OpenEvidence founder Daniel Nadler said access to medical knowledge should not depend on where a doctor or patient lives. The companies have not disclosed the financial details of the partnership.
OpenEvidence Uses Medical Research to Answer Doctors’ Questions
OpenEvidence is a medical knowledge platform that helps doctors find answers to clinical questions using peer-reviewed research, medical literature and treatment guidelines. The platform is already used by healthcare professionals in the U.S. and Europe. Nadler said U.S. clinicians used OpenEvidence 42 million times in August 2026 alone.
He also said doctors who used OpenEvidence will have treated several hundred million Americans during 2026. These figures were provided by OpenEvidence and have not been independently verified.
The platform draws on research and information from major medical organizations and publications. OpenEvidence lists collaborations involving The New England Journal of Medicine, JAMA and the JAMA Network, the National Comprehensive Cancer Network, Nature, Cochrane and several medical societies.
The Partnership Will Reach About 100 Countries
The partnership is expected to expand OpenEvidence’s access to about 100 countries, with a particular focus on regions where doctors may have less access to medical journals, specialist expertise and continuing medical education. Countries included in the initial rollout include:
- Uganda
- Angola
- Sudan
- Haiti
- Mongolia
The goal is to give doctors easier access to reliable medical information, including in healthcare systems with limited resources.
Smartphones could also help make the service more accessible. Nadler said that even in areas where healthcare facilities may not have reliable electricity, many doctors still have smartphones that can be used to access medical information.
OpenEvidence Is Adapting the System to Local Healthcare
A key part of the partnership is adapting the platform to local healthcare systems. Medical conditions, available treatments and healthcare resources can vary widely between countries. A medical AI system built mainly around data and practices from wealthier countries may not fully account for local disease patterns, diagnostic tools or treatments available to patients.
OpenEvidence is already working with healthcare organizations in Rwanda and Botswana to adapt its tools to local needs. OpenEvidence founder Daniel Nadler said the systems being developed for these regions are intended to adjust to the local healthcare context.
This is important because simply translating a medical AI tool into another language does not make it suitable for a different healthcare system. Doctors may have access to different diagnostic tests, medicines and treatment options, while hospitals may also operate with different levels of infrastructure and resources.
The Partnership Aims to Address Gaps in Medical Knowledge
Many low and middle-income countries face shortages of doctors and medical specialists. Healthcare professionals may also have limited access to medical journals, research papers and specialist expertise.
AI-based clinical tools are being explored as a way to help doctors find and review large amounts of medical information more quickly. The Anthropic and OpenEvidence partnership aims to address some of these gaps by providing a specialized medical AI service at no cost in countries where access to medical resources can be more limited.
Dr. Ahmed Bendary, a cardiologist at Benha University in Egypt, told Reuters that bringing evidence-based clinical tools to countries outside the U.S. and Europe could be useful in areas where hospitals have limited access to major medical journals.
Medical AI Still Needs to Account for Local Conditions
The global rollout also highlights a key issue in healthcare AI: medical tools need to work within the conditions of the healthcare systems where they are used.
AI models trained mainly on information from wealthier countries may not fully reflect conditions in lower-income regions. Differences can include disease rates, diagnostic equipment, available medicines, treatment options and clinical practices.
OpenEvidence’s work in Rwanda and Botswana is part of its effort to address these differences. Instead of treating healthcare systems around the world as the same, the company is adapting its platform to local conditions.
The system is also intended to serve as a clinical decision-support tool, not a replacement for doctors. It is designed to help clinicians find and assess medical information while they make decisions about patient care.
Anthropic Is Expanding Its Healthcare and Life Sciences Work
The partnership comes as Anthropic expands its work in healthcare and life sciences. In September 2026, the company introduced its Life Sciences Verification Program, which gives approved life-science professionals access to certain Anthropic models with safeguards designed for biological research.
The program covers areas such as drug discovery, research biology, clinical development and manufacturing. Anthropic has also been expanding its work in biology and drug research. These efforts show the company’s broader interest in using its AI models for scientific and healthcare applications.
The OpenEvidence partnership extends that work into clinical decision support, while also expanding access to medical AI beyond the major markets where these tools are already widely available.
ALSO READ: Anthropic Blocks Five Cases of AI Misuse Linked to Biological Weapons
How Anthropic and OpenEvidence Could Expand Global Healthcare Access
The partnership could help make medical research and clinical information more accessible to doctors in countries where healthcare resources are limited.
The initiative does not solve larger healthcare problems such as shortages of doctors, medicines, diagnostic equipment or reliable electricity. However, it could address one specific challenge: limited access to medical knowledge.
By giving clinicians free access to a medical AI platform, the companies aim to make it easier for doctors to find research, treatment guidelines and other medical information while caring for patients.
The partnership also shows that expanding medical AI requires more than making an AI model available. Reliable medical evidence, local adaptation, clinical oversight and accuracy will all be important for these tools to work effectively in different healthcare systems.
For Anthropic and OpenEvidence, the next step will be testing how well the platform performs across different regions and healthcare settings while maintaining the reliability expected from a clinical decision-support tool.